Intercept Pharma Europe Ltd.
$5.9M 0 recipients
Compare payment profiles
CMS Open Payments · Program Year 2024
Ipsen Innovation
Ipsen Innovation reported $5,847,337.71 across General Payments, Research, and Ownership to 124 physicians and teaching hospitals across 4,466 transactions.
- $5.8M
- All-tracks total
- 4,466
- Transactions
- 124
- Recipients
- +$207.3K
- General Payments vs PY2023
Ipsen Innovation reported $5,847,337.71 across all CMS Open Payments tracks (General + Research + Ownership) to 124 physicians and teaching hospitals in Program Year 2024 - ranking #250 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $349,467.12, averaging $47.2K per recipient.
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer ipsen-innovation Ipsen Innovation
$5.8M · #250/1,925 · 0.0% industry · PY2024
- TOT $5.8M
- RANK #250
- SHARE 0.0%
- TXN 4,466
- RCP 124
- CAT 4
- GEN $349.5K
- ΔGEN +$207.3K
- TOP1 13.8%
- PY 2024
Volume peers
Nearest volume peer: Intercept Pharma Europe Ltd. ($5.9M)
Ipsen Innovation sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
Ipsen Innovation's CMS-reported General Payments increased by $207.3K (+145.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: IPSEN INNOVATIONPY2023: IPSEN INNOVATIONPY2024: Ipsen Innovation. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $142,118.95
- PY2024
- $349,467.12
What the Data Shows for Ipsen Innovation
Rank #250 of 1,925 companies in CMS Open Payments for 2024 belongs to Ipsen Innovation, which reported $5,847,337.71 across 4,466 transactions to 124 recipients - a comparatively small 0.0% slice of all industry payments reported nationwide for the year. Averages work out to $1.3K per transaction and $47.2K per recipient.
The 4-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $226.8K, accounting for 64.9% of this company's General Payments and 54 transactions.
General Payment Breakdown by Type
Across 4 types of general payments, Ipsen Innovation's largest category was "Consulting Fee" at $226.8K - 64.9% of General Payments.
Ipsen Innovation reports 4 general-payment categories - the top three are Consulting Fee (64.9%), Travel and Lodging (22.7%), and Compensation for Services Other Than Consulting (11.2%). The remaining 1 category make up 1.2% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How Ipsen Innovation divides its payments
General-payment categories, ordered by reported total
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $226.8K | 54 | 64.9% |
| Travel and Lodging | $79.2K | 48 | 22.7% |
| Compensation for Services Other Than Consulting | $39.1K | 2 | 11.2% |
| Food and Beverage | $4.3K | 20 | 1.2% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $191,143.93 (54.7%) of $349,467.12 in this company's General Payments records across 51 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for Ipsen Innovation
The five named recipients with the highest reported General Payments from this company
- 1
Christopher L Bowlus
$48,265.65 across 9 reported transactions
- 2
Jack David Schim
$42,013.98 across 10 reported transactions
- 3
Atul Patel
$41,626.86 across 9 reported transactions
- 4
The Childrens Hospital Of Philadelp
$33,332.00 across 1 reported transactions
- 5
Monica Verduzco-Gutierrez
$25,905.44 across 7 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as Ipsen Innovation's, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about Ipsen Innovation.
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with Ipsen Innovation.
Showing 6 of 1,924 companies with CMS-reported payment data.
OMNIlife science, Inc
$5.8M 829 recipients
Compare payment profiles
Currax Pharmaceuticals LLC
$5.9M 7,546 recipients
Compare payment profiles
AxioMed LLC
$5.8M 1 recipients
Compare payment profiles
Linvatec Corporation
$5.8M 2,929 recipients
Compare payment profiles
Renalytix AI, Inc.
$5.9M 1,559 recipients
Compare payment profiles
Data sourced from CMS Open Payments (Physician Payments Sunshine Act). See our methodology for details. Retrieved and formatted by PlainPharmaWatch
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.